Skip to main content
Publications
Djibo DA, Margulis AV, McMahill-Walraven CN, Saltus C, Shuminski P, Kaye JA, Johannes C, Caligaert B, Libertin M, Graham S. Performance of endometrial cancer case finding algorithms among women with select comorbidities in US claims data. Poster presented at the 2022 North American Menopause Society Meeting; October 13, 2022. Atlanta, GA.
Veluswamy R, Ahn MJ, Nagar S, Affi R, Agulnik J, Shih JY, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI, Davis K, Kahangire DA, Servidio L, di Perna C, Lin SH. Surgical resection, treatment patterns and outcomes in patients (pts) with early-stage non-small cell lung cancer (NSCLC): interim analysis of a global real-world study. Poster presented at the 2022 International Thoracic Surgical Oncology Summit; September 30, 2022. New York, NY.
Spira A, Zhou X, Liao L, Yu E, Chen L, Lau A, Wang Y, Gnanasakthy A, Radford J, Hamadani M. Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2). Poster presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022); September 28, 2022. Houston, TX.
Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Gnanasakthy A, Taylor K, Jamotte A, Majer I, Kang YK. Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6. Poster presented at the 2022 ESMO Annual Conference; September 9, 2022. Paris, France.
Saigi-Morgui N, Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud SZ, McMahon P, Perez-Gutthann S, Rivero-Ferrer E. Acute myocardial infarction, stroke, and MACE in COPD patients treated with aclidinium and other inhaled bronchodilators. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.
Garcia de Albeniz X, Polo R, Teran C, Morales M, Rial-Crestelo D, Garcinuno MA, Garcia del Toro M, Hita C, Gomez-Sirvent JL, Buzon L, Diaz de Santiago A, Perez JL, Sanz J, Bachiller P, Martinez E, Diaz-Brito V, Masia M, Hernandez-Torres A, Guerra J, Arazo P, Arribas J, Martinez de Salazar P, Moreno S, Hernan MA, Del Amo J. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. A randomized clinical trial. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Estimating the historical population-level impact of PCV13 national immunization programs on invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States. Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Non-vaccine serotype population-level trends for invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States. Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.
Diez-Campelo M, Yucel A, Goyal R, Parikh R, Dhuliawala S, Jimenez M, Sluga-O'Callaghan M, Hughes C, Tang D, Germing U. Systemic therapy utilization and hematologic outcomes in lower-risk myelodysplastic syndromes (LR-MDS): findings from a real-world medical record review study in the US, UK, and Europe (EU). Poster presented at the 2022 European Hematology Association Hybrid Congress; June 10, 2022. Vienna, Austria.
Spira A, Liao L, Zhou X, Gnanasakthy A, Chen L, Ungar D, Yu E, Kilavuz T, Radford J, Hamadani M. Health-related quality of life and tolerability of loncastuximab tesirine in high-risk patients with relapsed/refractory diffuse large B-cell lymphoma treated in a phase 2 clinical trial (LOTIS 2). Poster presented at the 2022 EHA Congress; June 9, 2022. Vienna, Austria.
Lin SH, Ahn M, Nagar S, Affi R, Agulnik J, Shih J, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI, Davis K, Kahangire DA, Servidio L, Veluswamy R. Treatment patterns and outcomes in resectable early stage NSCLC: interim analysis of a global real-world study. Poster presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2022. Chicago, IL.
Paller A, Siegfried E, Marron SE, Clark M, Kosa K, Whalley D, Chao J, Bansal A, Chuang CC, Wang Z. Development and validation of a caregiver-reported numeric rating scale for measuring sleep quality in children aged 6 months to 5 years with atopic dermatitis. Poster presented at the 2022 Society for Investigative Dermatology (SID) Annual Meeting; May 2022. Portland, OR.
Paller A, Siegfried E, Marron SE, Clark M, Harris N, Qin S, Chao J, Bansal A, Chuang CC, Wang Z. Development and validation of a caregiver-reported numeric rating scale for measuring skin pain in children (aged 6 months to 5 years) with atopic dermatitis. Poster presented at the 2022 Society for Investigative Dermatology (SID) Annual Meeting; May 2022. Portland, OR.
Spira A, Liao L, Zhou X, Sherif B, Chen L, Ungar D, Yu E, Radford J, Hamadani M. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in older versus younger patients with relapsed/refractory diffuse large b-cell lymphoma treated in a phase 2 clinical trial (LOTIS-2). Poster presented at the National Comprehensive Cancer Network (NCCN) 2022 Virtual Annual Conference; March 31, 2022.
Prabhu V, Kelkar S, Corman S, Macahilig C, Rusibamayila N, Odak S, Duska L. Treatment patterns, real-world outcomes, and resource use in patients with non-MSI-high or mismatch repair proficient advanced endometrial cancer. Poster presented at the 2022 Virtual Hem/Onc Pharmacists Assoc (HOPA) Annual Conference; March 30, 2022. Boston, MA.